X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs CADILA HEALTHCARE - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB CADILA HEALTHCARE DR. REDDYS LAB/
CADILA HEALTHCARE
 
P/E (TTM) x 29.1 17.6 164.9% View Chart
P/BV x 3.1 4.2 74.6% View Chart
Dividend Yield % 0.8 1.0 86.3%  

Financials

 DR. REDDYS LAB   CADILA HEALTHCARE
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
CADILA HEALTHCARE
Mar-18
DR. REDDYS LAB/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs2,788558 499.6%   
Low Rs1,902362 526.1%   
Sales per share (Unadj.) Rs860.8116.3 740.2%  
Earnings per share (Unadj.) Rs57.117.9 319.4%  
Cash flow per share (Unadj.) Rs122.023.1 527.4%  
Dividends per share (Unadj.) Rs20.003.50 571.4%  
Dividend yield (eoy) %0.90.8 112.0%  
Book value per share (Unadj.) Rs757.785.4 887.1%  
Shares outstanding (eoy) m165.911,023.74 16.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.74.0 68.9%   
Avg P/E ratio x41.125.7 159.7%  
P/CF ratio (eoy) x19.219.9 96.7%  
Price / Book Value ratio x3.15.4 57.5%  
Dividend payout %35.019.6 178.9%   
Avg Mkt Cap Rs m389,034470,664 82.7%   
No. of employees `00023.511.8 199.0%   
Total wages/salary Rs m32,14918,545 173.4%   
Avg. sales/employee Rs Th6,070.810,072.7 60.3%   
Avg. wages/employee Rs Th1,366.61,569.1 87.1%   
Avg. net profit/employee Rs Th402.51,547.7 26.0%   
INCOME DATA
Net Sales Rs m142,810119,049 120.0%  
Other income Rs m1,5521,132 137.1%   
Total revenues Rs m144,362120,181 120.1%   
Gross profit Rs m23,51228,475 82.6%  
Depreciation Rs m10,7725,388 199.9%   
Interest Rs m788911 86.5%   
Profit before tax Rs m13,50423,308 57.9%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,3805,644 77.6%   
Profit after tax Rs m9,46818,292 51.8%  
Gross profit margin %16.523.9 68.8%  
Effective tax rate %32.424.2 133.9%   
Net profit margin %6.615.4 43.1%  
BALANCE SHEET DATA
Current assets Rs m104,98482,005 128.0%   
Current liabilities Rs m68,93860,720 113.5%   
Net working cap to sales %25.217.9 141.2%  
Current ratio x1.51.4 112.8%  
Inventory Days Days7473 101.7%  
Debtors Days Days10498 105.4%  
Net fixed assets Rs m104,38583,703 124.7%   
Share capital Rs m8301,024 81.1%   
"Free" reserves Rs m124,88686,421 144.5%   
Net worth Rs m125,71687,445 143.8%   
Long term debt Rs m25,08925,551 98.2%   
Total assets Rs m225,443180,653 124.8%  
Interest coverage x18.126.6 68.2%   
Debt to equity ratio x0.20.3 68.3%  
Sales to assets ratio x0.60.7 96.1%   
Return on assets %4.510.6 42.8%  
Return on equity %7.520.9 36.0%  
Return on capital %9.722.0 44.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m72,62342,683 170.1%   
Fx outflow Rs m18,91611,242 168.3%   
Net fx Rs m53,70731,441 170.8%   
CASH FLOW
From Operations Rs m18,0309,193 196.1%  
From Investments Rs m-14,883-9,737 152.8%  
From Financial Activity Rs m-4,440515 -862.1%  
Net Cashflow Rs m-1,236-29 4,262.1%  

Share Holding

Indian Promoters % 25.5 74.8 34.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 8.3 65.1%  
FIIs % 35.3 5.9 598.3%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 11.0 139.1%  
Shareholders   75,885 44,069 172.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   GLENMARK PHARMA  FULFORD INDIA  MERCK LTD  DIVIS LABORATORIES  UNICHEM LAB  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

DR. LAL PATHLABS LTD Surges by 7%; BSE HEALTHCARE Index Up 1.6% (Market Updates)

Aug 17, 2018 | Updated on Aug 17, 2018

DR. LAL PATHLABS LTD share price has surged by 7% and its current market price is Rs 1,040. The BSE HEALTHCARE is up by 1.6%. The top gainers in the BSE HEALTHCARE Index are DR. LAL PATHLABS LTD (up 7.4%) and CADILA HEALTHCARE (up 5.4%). The top losers are THYROCARE TECHNOLOGIES and SANOFI INDIA (down 0.2%).

CADILA HEALTHCARE Surges by 5%; BSE HEALTHCARE Index Up 1.4% (Market Updates)

Aug 17, 2018 | Updated on Aug 17, 2018

CADILA HEALTHCARE share price has surged by 5% and its current market price is Rs 358. The BSE HEALTHCARE is up by 1.4%. The top gainers in the BSE HEALTHCARE Index is CADILA HEALTHCARE (up 5.2%). The top losers are THYROCARE TECHNOLOGIES and PFIZER .

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Aug 17, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS